盘龙药业获CNAS国家实验室认证 质量管控体系达行业最高标准

Core Points - Panlong Pharmaceutical (002864) has successfully passed the rigorous evaluation by the China National Accreditation Service for Conformity Assessment (CNAS) and obtained the laboratory accreditation certificate, effective from June 9, 2025, to June 8, 2031, marking a new benchmark for high-quality development in the traditional Chinese medicine industry [2][3] - The CNAS accreditation signifies that the company's quality control system meets the highest international standards, allowing for mutual recognition of testing data across over 100 economies globally, enhancing the legal authority and international credibility of its testing results [2][3] Company Upgrades - The accreditation will drive upgrades in three key areas: - Research and Development: Accelerating the validation of the effectiveness of new traditional Chinese medicines through a high-standard testing platform [3] - Production: Ensuring a lean production process that guarantees a comprehensive traceability system from raw materials to finished products [3] - Market: Strengthening customer trust and providing international recognition to the "Panlong" brand [3] Strategic Validation - The CNAS recognition is seen as validation of the company's strategy to build its brand on quality, with plans to integrate modern testing technologies with traditional Chinese medicine wisdom, ensuring that every medicinal material and product meets global standards [3]